File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Differential effects of anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive fractions on human colorectal cancer models
  • Basic View
  • Metadata View
  • XML View
TitleDifferential effects of anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive fractions on human colorectal cancer models
 
AuthorsChu, ESM1
Sze, SCW1
Cheung, HP1
Wong, KL1
Liu, Q1
Ng, TB2
Tong, Y1
 
KeywordsAnti-metastatic
Chinese medicinal formulation
Colorectal cancer
Matrix metalloproteinases
Tian-Xian liquid
Vascular endothelial growth factor
 
Issue Date2011
 
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/jethpharm
 
CitationJournal Of Ethnopharmacology, 2011, v. 137 n. 1, p. 403-413 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jep.2011.05.035
 
AbstractAim of study: This study aimed to elucidate and compare the anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive components namely butanol (BU), ethyl-acetate (EA) and aqueous (WA) fractions on human colorectal cancer in vitro (HT-29 cancer cells) and in vivo (nude mouse xenografts). Materials and methods: The anti-proliferative effects of TXL and its bioactive components in HT-29 cells were determined by MTT assay. Their modulations on the potential angiogenic and metastatic marker expressions on HT-29 cells and xenografts were investigated by real-time PCR and Western blot at transcriptional and translational levels, respectively. For the in vitro study, migration abilities of HT-29 cells were determined using wound healing assay. For the in vivo study, daily measurements of the tumor size and volume of the xenografts were also performed. Results: TXL, BU, EA and WA effectively inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner. The IC 50 value of TXL on HT-29 cells was obtained after incubation with 1% (v/v) TXL for 4 h; whereas IC 50 values were obtained for the following bioactive components: BU at 1.25% (v/v); EA at 5% (v/v); and WA at 0.3125% (v/v). It was found that 1% (v/v) TXL significantly down-regulated MMP2 and MMP7 expression at both transcriptional and translational levels and it reduced MMP9 and VEGF protein expression in vitro. TXL decreased the metastatic ability of HT-29 cells as demonstrated by wound healing assay. TXL and its bioactive fractions caused no significant changes in the body weight indicating lack of toxicity to the xenografts. Conclusions: In summary, TXL multi-targeted to down-regulate the metastatic markers in both in vitro and in vivo models. However, the effects of its bioactive fractions were not obvious. This study profoundly elucidated the anti-proliferative mechanism of TXL, which is vital for the development of future anti-cancer regime in Chinese medicinal formulations. © 2011 Elsevier Ireland Ltd All rights reserved.
 
ISSN0378-8741
2013 Impact Factor: 2.939
2013 SCImago Journal Rankings: 1.149
 
DOIhttp://dx.doi.org/10.1016/j.jep.2011.05.035
 
ISI Accession Number IDWOS:000295236700050
Funding AgencyGrant Number
Seed Funding Programme for Applied Research200807160015
China-Japan Feida Union Company Limited
Funding Information:

The research study was supported in part by a grant from Seed Funding Programme for Applied Research (no.: 200807160015) and contract research funding from China-Japan Feida Union Company Limited.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorChu, ESM
 
dc.contributor.authorSze, SCW
 
dc.contributor.authorCheung, HP
 
dc.contributor.authorWong, KL
 
dc.contributor.authorLiu, Q
 
dc.contributor.authorNg, TB
 
dc.contributor.authorTong, Y
 
dc.date.accessioned2011-07-27T02:12:56Z
 
dc.date.available2011-07-27T02:12:56Z
 
dc.date.issued2011
 
dc.description.abstractAim of study: This study aimed to elucidate and compare the anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive components namely butanol (BU), ethyl-acetate (EA) and aqueous (WA) fractions on human colorectal cancer in vitro (HT-29 cancer cells) and in vivo (nude mouse xenografts). Materials and methods: The anti-proliferative effects of TXL and its bioactive components in HT-29 cells were determined by MTT assay. Their modulations on the potential angiogenic and metastatic marker expressions on HT-29 cells and xenografts were investigated by real-time PCR and Western blot at transcriptional and translational levels, respectively. For the in vitro study, migration abilities of HT-29 cells were determined using wound healing assay. For the in vivo study, daily measurements of the tumor size and volume of the xenografts were also performed. Results: TXL, BU, EA and WA effectively inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner. The IC 50 value of TXL on HT-29 cells was obtained after incubation with 1% (v/v) TXL for 4 h; whereas IC 50 values were obtained for the following bioactive components: BU at 1.25% (v/v); EA at 5% (v/v); and WA at 0.3125% (v/v). It was found that 1% (v/v) TXL significantly down-regulated MMP2 and MMP7 expression at both transcriptional and translational levels and it reduced MMP9 and VEGF protein expression in vitro. TXL decreased the metastatic ability of HT-29 cells as demonstrated by wound healing assay. TXL and its bioactive fractions caused no significant changes in the body weight indicating lack of toxicity to the xenografts. Conclusions: In summary, TXL multi-targeted to down-regulate the metastatic markers in both in vitro and in vivo models. However, the effects of its bioactive fractions were not obvious. This study profoundly elucidated the anti-proliferative mechanism of TXL, which is vital for the development of future anti-cancer regime in Chinese medicinal formulations. © 2011 Elsevier Ireland Ltd All rights reserved.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Ethnopharmacology, 2011, v. 137 n. 1, p. 403-413 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jep.2011.05.035
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.jep.2011.05.035
 
dc.identifier.epage413
 
dc.identifier.hkuros188145
 
dc.identifier.isiWOS:000295236700050
Funding AgencyGrant Number
Seed Funding Programme for Applied Research200807160015
China-Japan Feida Union Company Limited
Funding Information:

The research study was supported in part by a grant from Seed Funding Programme for Applied Research (no.: 200807160015) and contract research funding from China-Japan Feida Union Company Limited.

 
dc.identifier.issn0378-8741
2013 Impact Factor: 2.939
2013 SCImago Journal Rankings: 1.149
 
dc.identifier.issue1
 
dc.identifier.openurl
 
dc.identifier.pmid21669277
 
dc.identifier.scopuseid_2-s2.0-80052035168
 
dc.identifier.spage403
 
dc.identifier.urihttp://hdl.handle.net/10722/136308
 
dc.identifier.volume137
 
dc.languageeng
 
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/jethpharm
 
dc.publisher.placeIreland
 
dc.relation.ispartofJournal of Ethnopharmacology
 
dc.relation.referencesReferences in Scopus
 
dc.subjectAnti-metastatic
 
dc.subjectChinese medicinal formulation
 
dc.subjectColorectal cancer
 
dc.subjectMatrix metalloproteinases
 
dc.subjectTian-Xian liquid
 
dc.subjectVascular endothelial growth factor
 
dc.titleDifferential effects of anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive fractions on human colorectal cancer models
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Chu, ESM</contributor.author>
<contributor.author>Sze, SCW</contributor.author>
<contributor.author>Cheung, HP</contributor.author>
<contributor.author>Wong, KL</contributor.author>
<contributor.author>Liu, Q</contributor.author>
<contributor.author>Ng, TB</contributor.author>
<contributor.author>Tong, Y</contributor.author>
<date.accessioned>2011-07-27T02:12:56Z</date.accessioned>
<date.available>2011-07-27T02:12:56Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Journal Of Ethnopharmacology, 2011, v. 137 n. 1, p. 403-413</identifier.citation>
<identifier.issn>0378-8741</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/136308</identifier.uri>
<description.abstract>Aim of study: This study aimed to elucidate and compare the anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive components namely butanol (BU), ethyl-acetate (EA) and aqueous (WA) fractions on human colorectal cancer in vitro (HT-29 cancer cells) and in vivo (nude mouse xenografts). Materials and methods: The anti-proliferative effects of TXL and its bioactive components in HT-29 cells were determined by MTT assay. Their modulations on the potential angiogenic and metastatic marker expressions on HT-29 cells and xenografts were investigated by real-time PCR and Western blot at transcriptional and translational levels, respectively. For the in vitro study, migration abilities of HT-29 cells were determined using wound healing assay. For the in vivo study, daily measurements of the tumor size and volume of the xenografts were also performed. Results: TXL, BU, EA and WA effectively inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner. The IC 50 value of TXL on HT-29 cells was obtained after incubation with 1% (v/v) TXL for 4 h; whereas IC 50 values were obtained for the following bioactive components: BU at 1.25% (v/v); EA at 5% (v/v); and WA at 0.3125% (v/v). It was found that 1% (v/v) TXL significantly down-regulated MMP2 and MMP7 expression at both transcriptional and translational levels and it reduced MMP9 and VEGF protein expression in vitro. TXL decreased the metastatic ability of HT-29 cells as demonstrated by wound healing assay. TXL and its bioactive fractions caused no significant changes in the body weight indicating lack of toxicity to the xenografts. Conclusions: In summary, TXL multi-targeted to down-regulate the metastatic markers in both in vitro and in vivo models. However, the effects of its bioactive fractions were not obvious. This study profoundly elucidated the anti-proliferative mechanism of TXL, which is vital for the development of future anti-cancer regime in Chinese medicinal formulations. &#169; 2011 Elsevier Ireland Ltd All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier Ireland Ltd. The Journal&apos;s web site is located at http://www.elsevier.com/locate/jethpharm</publisher>
<relation.ispartof>Journal of Ethnopharmacology</relation.ispartof>
<subject>Anti-metastatic</subject>
<subject>Chinese medicinal formulation</subject>
<subject>Colorectal cancer</subject>
<subject>Matrix metalloproteinases</subject>
<subject>Tian-Xian liquid</subject>
<subject>Vascular endothelial growth factor</subject>
<title>Differential effects of anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive fractions on human colorectal cancer models</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0378-8741&amp;volume=137&amp;issue=1&amp;spage=403&amp;epage=413&amp;date=2011&amp;atitle=Differential+effects+of+anti-metastatic+mechanism+of+Tian-Xian+Liquid+(TXL)+and+its+bioactive+fractions+on+human+colorectal+cancer+models</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.jep.2011.05.035</identifier.doi>
<identifier.pmid>21669277</identifier.pmid>
<identifier.scopus>eid_2-s2.0-80052035168</identifier.scopus>
<identifier.hkuros>188145</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-80052035168&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>137</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>403</identifier.spage>
<identifier.epage>413</identifier.epage>
<identifier.isi>WOS:000295236700050</identifier.isi>
<publisher.place>Ireland</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong Li Ka Shing Faculty of Medicine
  2. Chinese University of Hong Kong